Targeting tumor vasculature with an oncolytic virus.

Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada.
Molecular Therapy (Impact Factor: 7.04). 03/2011; 19(5):886-94. DOI: 10.1038/mt.2011.26
Source: PubMed

ABSTRACT Oncolytic viruses (OVs) have been engineered or selected for cancer cell-specific infection however, we have found that following intravenous administration of vesicular stomatitis virus (VSV), tumor cell killing rapidly extends far beyond the initial sites of infection. We show here for the first time that VSV directly infects and destroys tumor vasculature in vivo but leaves normal vasculature intact. Three-dimensional (3D) reconstruction of infected tumors revealed that the majority of the tumor mass lacks significant blood flow in contrast to uninfected tumors, which exhibit relatively uniform perfusion. VSV replication in tumor neovasculature and spread within the tumor mass, initiates an inflammatory reaction including a neutrophil-dependent initiation of microclots within tumor blood vessels. Within 6 hours of intravenous administration of VSV and continuing for at least 24 hours, we observed the initiation of blood clots within the tumor vasculature whereas normal vasculature remained clot free. Blocking blood clot formation with thrombin inhibitors prevented tumor vascular collapse. Our results demonstrate that the therapeutic activity of an OV can go far beyond simple infection and lysis of malignant cells.

  • [Show abstract] [Hide abstract]
    ABSTRACT: We sought proof of principle that tumor targeting ligands could be displayed on the surface of vesicular stomatitis virus (VSV) by engineering its glycoprotein. Here we successfully rescued VSVs displaying tumor vasculature targeting ligands. Using a rational approach we investigated various feasible insertion sites on VSV G for display of tumor vasculature targeting ligands, cyclicRGD and echistatin. We found seven sites on VSV G that tolerated insertion of the nine residue length cRGD peptide, two of which could tolerate insertion of the 49aa echistatin domain. All of the ligand-displaying viruses replicated as well as the parental virus. In vitro studies demonstrated that the VSV-echistatin viruses specifically bind to targeted integrins. Since low density lipoprotein receptor (LDLR) was recently identified as a major receptor for VSV, we investigated the entry of ligand displaying viruses after masking LDLR. This experiment showed that the modified viruses can enter the cell independently of LDLR whereas entry of unmodified virus is significantly blocked by specific monoclonal antibody against LDLR. Both parental and ligand displaying viruses displayed equal oncolytic efficacy in a syngeneic mouse myeloma model. We further demonstrated that single chain antibody fragments against tumor specific antigens can be inserted at the N-terminus of the G protein and corresponding replication competent VSVs can be rescued efficiently. Overall, we have demonstrated that functional tumor targeting ligands can be displayed on replication competent VSVs without perturbing viral growth and oncolytic efficacy. This study provides a rational foundation for the future development of fully retargeted oncolytic VSVs.
    Journal of Virology 10/2013; · 5.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.
    Chinese journal of cancer 11/2011; 30(12):805-14.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Viruses have demonstrated strong potential for the therapeutic targeting of glioblastoma stem cells (GSCs). In this study, the use of a herpes simplex virus carrying endostatin-angiostatin (VAE) as a novel therapeutic targeting strategy for glioblastoma-derived cancer stem cells was investigated. We isolated six stable GSC-enriched cultures from 36 human glioblastoma specimens and selected one of the stable GSCs lines for establishing GSC-carrying orthotopic nude mouse models. The following results were obtained: (a) VAE rapidly proliferated in GSCs and expressed endo-angio in vitro and in vivo 48 h and 10 d after infection, respectively; (b) compared with the control gliomas treated with rHSV or Endostar, the subcutaneous gliomas derived from the GSCs showed a significant reduction in microvessel density after VAE treatment; (c) compared with the control, a significant improvement was observed in the length of the survival of mice with intracranial and subcutaneous gliomas treated with VAE; (d) MRI analysis showed that the tumor volumes of the intracranial gliomas generated by GSCs remarkably decreased after 10 d of VAE treatment compared with the controls. In conclusion, VAE demonstrated oncolytic therapeutic efficacy in animal models of human GSCs and expressed an endostatin-angiostatin fusion gene, which enhanced antitumor efficacy most likely by restricting tumor microvasculature development.
    PLoS ONE 01/2014; 9(4):e95872. · 3.53 Impact Factor


Available from
Jun 10, 2014